Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.

Caminati M, Cegolon L, Vianello A, Chieco Bianchi F, Festi G, Marchi MR, Micheletto C, Mazza F, Tognella S, Senna G.

Expert Rev Respir Med. 2019 Dec;13(12):1205-1212. doi: 10.1080/17476348.2019.1676734. Epub 2019 Oct 16.

PMID:
31592700
2.

Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience.

Vianello A, Caminati M, Andretta M, Menti AM, Tognella S, Senna G, Degli Esposti L.

World Allergy Organ J. 2019 May 10;12(4):100032. doi: 10.1016/j.waojou.2019.100032. eCollection 2019. No abstract available.

3.

Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.

Bourbeau J, Granados D, Roze S, Durand-Zaleski I, Casan P, Köhler D, Tognella S, Viejo JL, Dal Negro RW, Kessler R.

Int J Chron Obstruct Pulmon Dis. 2019 Mar 14;14:645-657. doi: 10.2147/COPD.S173057. eCollection 2019.

4.

Relevance of Th2 markers in the assessment and therapeutic management of severe allergic asthma: a real life perspective.

Caminati M, Vianello A, Chieco Bianchi F, Festi G, Guarnieri G, Marchi MR, Micheletto C, Olivieri M, Tognella S, Guerriero M, Senna G; NEONET Study Group.

J Investig Allergol Clin Immunol. 2019 Jan 24:0. doi: 10.18176/jiaci.0379. [Epub ahead of print]

5.

COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD.

Kessler R, Casan-Clara P, Koehler D, Tognella S, Viejo JL, Dal Negro RW, Díaz-Lobato S, Reissig K, Rodríguez González-Moro JM, Devouassoux G, Chavaillon JM, Botrus P, Arnal JM, Ancochea J, Bergeron-Lafaurie A, De Abajo C, Randerath WJ, Bastian A, Cornelissen CG, Nilius G, Texereau JB, Bourbeau J.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701612. doi: 10.1183/13993003.01612-2017. Print 2018 Jan.

6.

Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.

Caminati M, Senna G, Stefanizzi G, Bellamoli R, Longhi S, Chieco-Bianchi F, Guarnieri G, Tognella S, Olivieri M, Micheletto C, Festi G, Bertocco E, Mazza M, Rossi A, Vianello A; North East Omalizumab Network study group.

BMC Pulm Med. 2016 Aug 25;16(1):128. doi: 10.1186/s12890-016-0290-5. Review.

7.

An international randomized study of a home-based self-management program for severe COPD: the COMET.

Bourbeau J, Casan P, Tognella S, Haidl P, Texereau JB, Kessler R.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 28;11:1447-51. doi: 10.2147/COPD.S107151. eCollection 2016.

8.

Cognitive dysfunction in severe chronic obstructive pulmonary disease (COPD) with or without Long-Term Oxygen Therapy (LTOT).

Dal Negro RW, Bonadiman L, Bricolo FP, Tognella S, Turco P.

Multidiscip Respir Med. 2015 Apr 19;10(1):17. doi: 10.1186/s40248-015-0013-4. eCollection 2015.

9.

Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update.

Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S.

Clinicoecon Outcomes Res. 2015 Mar 16;7:153-9. doi: 10.2147/CEOR.S77504. eCollection 2015.

10.

Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values.

Dal Negro RW, Bonadiman L, Tognella S, Bricolo FP, Turco P.

Int J Chron Obstruct Pulmon Dis. 2014 Jun 26;9:675-83. doi: 10.2147/COPD.S63485. eCollection 2014.

11.

Omalizumab management beyond clinical trials: the added value of a network model.

Caminati M, Senna G, Chieco Bianchi F, Marchi MR, Vianello A, Micheletto C, Pomari C, Tognella S, Savoia F, Mirisola V, Rossi A; NEONET Study Group.

Pulm Pharmacol Ther. 2014 Oct;29(1):74-9. doi: 10.1016/j.pupt.2014.01.007. Epub 2014 Feb 6.

PMID:
24508951
12.

Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity.

Dal Negro RW, Tognella S, Guerriero M, Micheletto C.

Multidiscip Respir Med. 2013 May 14;8(1):32. doi: 10.1186/2049-6958-8-32.

13.

Essential amino acid supplementation in patients with severe COPD: a step towards home rehabilitation.

Dal Negro RW, Testa A, Aquilani R, Tognella S, Pasini E, Barbieri A, Boschi F.

Monaldi Arch Chest Dis. 2012 Jun;77(2):67-75.

14.

Changes in blood hemoglobin and blood gases PaO2 and PaCO2 in severe COPD overa three-year telemonitored program of long-term oxygen treatment.

Dal Negro RW, Tognella S, Bonadiman L, Turco P.

Multidiscip Respir Med. 2012 Jul 17;7(1):15. doi: 10.1186/2049-6958-7-15.

15.

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.

Dal Negro RW, Tognella S, Pradelli L.

J Asthma. 2012 Oct;49(8):843-8. doi: 10.3109/02770903.2012.717659. Epub 2012 Sep 7.

PMID:
22954018
16.

Use of aerosols in bronchiectasis patients.

Dal Negro RW, Micheletto C, Tognella S.

Monaldi Arch Chest Dis. 2011 Sep;75(3):185-93. Review.

17.

Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.

Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S.

Eur Ann Allergy Clin Immunol. 2011 Mar;43(2):45-53.

PMID:
21608372
18.

Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.

Dal Negro RW, Guerriero M, Micheletto C, Tognella S, Visconti M.

J Asthma. 2011 Jun;48(5):437-41. doi: 10.3109/02770903.2011.578316.

PMID:
21599560
19.

Changes of clinical outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18 mcg od for twenty-four months.

Dal Negro RW, Bonadiman L, Micheletto C, Tognella S, Turati C, Turco P.

Pulm Pharmacol Ther. 2011 Aug;24(4):373-6. doi: 10.1016/j.pupt.2011.03.004. Epub 2011 Mar 21.

PMID:
21421072
20.

Reference urinary LTE4 levels in normal individuals: a pilot study.

Dal Negro RW, Visconti M, Micheletto C, Tognella S, Guerriero M.

Eur Ann Allergy Clin Immunol. 2011 Feb;43(1):22-8.

PMID:
21409858
21.

Erdosteine affects eicosanoid production in COPD.

Dal Negro RW, Visconti M, Tognella S, Micheletto C.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):41-5.

PMID:
21176724
22.

The impact of LABA+ICS fixed combinations on morbidity and economic burden of COPD in Italy: a six-year observational study.

Dal Negro R, Bonadiman L, Tognella S, Micheletto C, Turco P.

Ther Adv Respir Dis. 2011 Apr;5(2):83-90. doi: 10.1177/1753465810386052. Epub 2010 Nov 18.

PMID:
21088038
23.

The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild and moderate asthma.

Micheletto C, Visconti M, Trevisan F, Tognella S, Bertacco S, Dal Negro RW.

Eur Ann Allergy Clin Immunol. 2010 Jun;42(3):120-4.

PMID:
20648775
24.

Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia.

Dal Negro RW, Aquilani R, Bertacco S, Boschi F, Micheletto C, Tognella S.

Monaldi Arch Chest Dis. 2010 Mar;73(1):25-33.

PMID:
20499791
25.

A MCh test pre-post esophageal acidification in detecting GER-related asthma.

Dal Negro RW, Tognella S, Micheletto C, Sandri M, Guerriero M.

J Asthma. 2009 May;46(4):351-5. doi: 10.1080/02770900802712955.

PMID:
19484668
26.

Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.

Dal Negro R, Visconti M, Trevisan F, Bertacco S, Micheletto C, Tognella S.

Ther Adv Respir Dis. 2008 Oct;2(5):271-7. doi: 10.1177/1753465808096109. Epub 2008 Sep 3.

PMID:
19124377
27.

Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation.

Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C.

Adv Ther. 2008 Oct;25(10):1019-30. doi: 10.1007/s12325-008-0105-2. Erratum in: Adv Ther. 2008 Dec;25(12):1379.

PMID:
18821068
28.
29.

Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).

Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF.

Respir Med. 2008 Jan;102(1):92-101. Epub 2007 Sep 19.

30.

PIKO-1, an effective, handy device for the patient's personal PEFR and FEV1 electronic long-term monitoring.

Dal Negro RW, Micheletto C, Tognella S, Turati C, Bisato R, Guerriero M, Sandri M, Turco P.

Monaldi Arch Chest Dis. 2007 Jun;67(2):84-9.

PMID:
17695691
31.

Urinary LTE4 is higher after nasal provocation test with L-ASA in bronchial than in only nasal responders.

Micheletto C, Visconti M, Tognella S, Trevisan F, Dal Negro RW.

Eur Ann Allergy Clin Immunol. 2007 May;39(5):162-6.

PMID:
17626331
32.

Cost analysis of GER-induced asthma: a controlled study vs. atopic asthma of comparable severity.

Dal Negro RW, Turco P, Micheletto C, Tognella S, Bonadiman L, Guerriero M, Sandri M.

Respir Med. 2007 Aug;101(8):1814-20. Epub 2007 Apr 6.

33.
34.

The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.

Dal Negro RW, Micheletto C, Tognella S, Trevisan F, Guerriero M.

Eur Ann Allergy Clin Immunol. 2006 May;38(5):153-7.

PMID:
17058847
35.

Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics.

Micheletto C, Tognella S, Visconti M, Trevisan F, Dal Negro RW.

Respir Med. 2006 Dec;100(12):2144-50. Epub 2006 May 5.

36.

Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls.

Micheletto C, Visconti M, Tognella S, Facchini FM, Dal Negro RW.

Eur Ann Allergy Clin Immunol. 2006 Jan;38(1):20-3.

PMID:
16544584
37.

Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma.

Micheletto C, Tognella S, Guerriero M, Dal Negro R.

Eur Ann Allergy Clin Immunol. 2006 Jan;38(1):10-4.

PMID:
16544582
38.

Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma.

Micheletto C, Guerriero M, Tognella S, Dal Negro RW.

Respir Med. 2005 Jul;99(7):850-5. Epub 2005 Apr 8.

39.

Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo.

Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW.

Allergy. 2004 Mar;59(3):289-94.

PMID:
14982510
40.

Assessment of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic markers in steroids-naive nonatopic asthmatics.

Dal Negro R, Micheletto C, Tognella S, Turco P, Rossetti A, Cantini L.

Allergy. 2003 Oct;58(10):1018-22.

PMID:
14510719
42.

Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study.

Dal Negro R, Berto P, Tognella S, Quareni L; Global Outcomes in Lung Disease Study Group.

Monaldi Arch Chest Dis. 2002 Feb;57(1):3-9.

PMID:
12174698
43.

Evidence of adequacy of the performance of the Pulvinal by measuring through-device peak inspiratory flow rate in severe airways obstruction in adults and children.

Negro RD, Micheletto C, Tognella S, Clayton N, Cantini L, Woodcock A.

J Aerosol Med. 2001 Fall;14(3):343-9.

PMID:
11693846
44.

Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics.

Dal Negro R, Micheletto C, Tognella S, Mauroner L, Burti E, Turco P, Pomari C, Cantini L.

J Investig Allergol Clin Immunol. 1999 Jul-Aug;9(4):241-7.

PMID:
10513351
45.

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F.

Br J Cancer. 1999 Aug;80(12):1912-9.

46.

Prevalence of gastro-oesophageal reflux in asthmatics: an Italian study.

Dal Negro R, Pomari C, Micheletto C, Turco P, Tognella S.

Ital J Gastroenterol Hepatol. 1999 Jun-Jul;31(5):371-5.

PMID:
10470594
47.

Serum eosinophil cationic protein and bronchial hyperresponsiveness to hypoosmolar challenge in naive atopic asthmatics.

Dal Negro R, Tognella S, Micheletto C, Pomari C, Burti E, Mauroner L, Turco P.

J Investig Allergol Clin Immunol. 1998 Sep-Oct;8(5):294-9.

PMID:
9827426
48.

Pharmacokinetics of [14C] BBR 3053, an alkylating bisphosphonate, after single i.v. and multiple s.c. administration in rats.

Bernareggi A, Crippa MT, Bastrup U, Di Giovine S, Cesarini R, Tognella S.

Boll Chim Farm. 1997 Apr;136(4):304-7. No abstract available.

PMID:
9281891
49.

The in vitro binding kinetics of cisplatin to human plasma proteins is not affected by glutathione.

Torti L, Bernareggi A, Castoldi D, Formento ML, Cesarini R, Tognella S.

Boll Chim Farm. 1997 Apr;136(4):301-3. No abstract available.

PMID:
9281890
50.

Effects of moguisteine, a peripheral nonnarcotic antitussive agent, on airway inflammation in guinea-pigs in vivo.

Gallico L, Oggioni N, Dalla Rosa C, Ceserani R, Tognella S.

Eur Respir J. 1996 Mar;9(3):478-85.

Supplemental Content

Loading ...
Support Center